136 related articles for article (PubMed ID: 27763887)
1. Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance.
Rao LK; Flaker AM; Friedel CC; Kharasch ED
Anesthesiology; 2016 Dec; 125(6):1103-1112. PubMed ID: 27763887
[TBL] [Abstract][Full Text] [Related]
2. Stereoselective Ketamine Metabolism by Genetic Variants of Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase.
Wang PF; Neiner A; Kharasch ED
Anesthesiology; 2018 Oct; 129(4):756-768. PubMed ID: 30085944
[TBL] [Abstract][Full Text] [Related]
3. CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects.
Li Y; Jackson KA; Slon B; Hardy JR; Franco M; William L; Poon P; Coller JK; Hutchinson MR; Currow DC; Somogyi AA
Br J Clin Pharmacol; 2015 Aug; 80(2):276-84. PubMed ID: 25702819
[TBL] [Abstract][Full Text] [Related]
4. Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism.
Kharasch ED; Regina KJ; Blood J; Friedel C
Anesthesiology; 2015 Nov; 123(5):1142-53. PubMed ID: 26389554
[TBL] [Abstract][Full Text] [Related]
5. The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitro.
Li Y; Coller JK; Hutchinson MR; Klein K; Zanger UM; Stanley NJ; Abell AD; Somogyi AA
Drug Metab Dispos; 2013 Jun; 41(6):1264-72. PubMed ID: 23550066
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans.
Mössner LD; Schmitz A; Theurillat R; Thormann W; Mevissen M
Am J Vet Res; 2011 Nov; 72(11):1505-13. PubMed ID: 22023129
[TBL] [Abstract][Full Text] [Related]
7. Methadone pharmacogenetics in vitro and in vivo: Metabolism by CYP2B6 polymorphic variants and genetic variability in paediatric disposition.
Wang PF; Sharma A; Montana M; Neiner A; Juriga L; Reddy KN; Tallchief D; Blood J; Kharasch ED
Br J Clin Pharmacol; 2022 Nov; 88(11):4881-4893. PubMed ID: 35538637
[TBL] [Abstract][Full Text] [Related]
8. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
[TBL] [Abstract][Full Text] [Related]
9. Equine cytochrome P450 2B6--genomic identification, expression and functional characterization with ketamine.
Peters LM; Demmel S; Pusch G; Buters JT; Thormann W; Zielinski J; Leeb T; Mevissen M; Schmitz A
Toxicol Appl Pharmacol; 2013 Jan; 266(1):101-8. PubMed ID: 23142468
[TBL] [Abstract][Full Text] [Related]
10. Differences in Methadone Metabolism by CYP2B6 Variants.
Gadel S; Friedel C; Kharasch ED
Drug Metab Dispos; 2015 Jul; 43(7):994-1001. PubMed ID: 25897175
[TBL] [Abstract][Full Text] [Related]
11. Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
Peltoniemi MA; Saari TI; Hagelberg NM; Reponen P; Turpeinen M; Laine K; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 2011 Aug; 90(2):296-302. PubMed ID: 21716267
[TBL] [Abstract][Full Text] [Related]
12. Role of cytochrome P4502B6 in methadone metabolism and clearance.
Kharasch ED; Stubbert K
J Clin Pharmacol; 2013 Mar; 53(3):305-13. PubMed ID: 23361846
[TBL] [Abstract][Full Text] [Related]
13. Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6.
Gadel S; Crafford A; Regina K; Kharasch ED
Drug Metab Dispos; 2013 Apr; 41(4):709-13. PubMed ID: 23298862
[TBL] [Abstract][Full Text] [Related]
14. Modeling the norketamine metabolite in children and the implications for analgesia.
Herd DW; Anderson BJ; Holford NH
Paediatr Anaesth; 2007 Sep; 17(9):831-40. PubMed ID: 17683400
[TBL] [Abstract][Full Text] [Related]
15. Common Polymorphisms of CYP2B6 Influence Stereoselective Bupropion Disposition.
Kharasch ED; Crafford A
Clin Pharmacol Ther; 2019 Jan; 105(1):142-152. PubMed ID: 29756345
[TBL] [Abstract][Full Text] [Related]
16. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.
Desta Z; Saussele T; Ward B; Blievernicht J; Li L; Klein K; Flockhart DA; Zanger UM
Pharmacogenomics; 2007 Jun; 8(6):547-58. PubMed ID: 17559344
[TBL] [Abstract][Full Text] [Related]
17. Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients.
Yuce-Artun N; Baskak B; Ozel-Kizil ET; Ozdemir H; Uckun Z; Devrimci-Ozguven H; Suzen HS
Int J Clin Pharm; 2016 Apr; 38(2):388-94. PubMed ID: 26830411
[TBL] [Abstract][Full Text] [Related]
18. Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity.
Kharasch ED; Mitchell D; Coles R
J Clin Pharmacol; 2008 Apr; 48(4):464-74. PubMed ID: 18287571
[TBL] [Abstract][Full Text] [Related]
19. Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: a crucial role for the CYP2B6*6 allele.
Hwang IC; Park JY; Ahn HY; Kim KK; Suh HS; Ko KD; Kim KA
Clin Chim Acta; 2014 Jan; 428():77-81. PubMed ID: 24262967
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.
Gerber JG; Rhodes RJ; Gal J
Chirality; 2004 Jan; 16(1):36-44. PubMed ID: 14628297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
